Navigation Links
Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results
Date:11/6/2009

HOUSTON, Nov. 6 /PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX) today announced that the company will report financial results for the second quarter ended October 23, 2009 of its fiscal year ending April 30, 2010 on Wednesday, November 18, 2009 at 5:00 PM EST. The company will conduct a conference call to discuss those results on Thursday, November 19, 2009 at 9:00 AM EST.

Fiscal Year 2010 Second Quarter Results Conference Call Instructions

To listen to the conference call live by telephone dial 877-313-8035 (if dialing from within the U.S.) or 706-679-4838 (if dialing from outside the U.S.). The conference ID is 40115998. Presentation slides will be available on-line at www.cyberonics.com no later than 8:00 AM EST on Thursday, November 19, 2009. A replay of the conference call will be available approximately two hours after the completion of the conference call by dialing 800-642-1687 (if dialing from within the U.S.) or 706-645-9291 (if dialing from outside the U.S.). The replay conference ID access code is 40115998. The replay will be available for one week on the above number and subsequently on the company's website for a period of six months.

About Cyberonics, Inc. and VNS Therapy(TM)

Cyberonics, Inc. (NASDAQ:CYBX) is a medical technology company with core expertise in neuromodulation. The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy(TM) System, which is FDA-approved for the treatments of epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers electrical pulsed signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.

Additional information on Cyberonics and VNS Therapy is available at www.cyberonics.com and

www.vnstherapy.com.

    CONTACT INFORMATION:
    Greg Browne, CFO
    Cyberonics, Inc.
    100 Cyberonics Blvd., Houston, TX 77058
    Main:  (281) 228-7262/Fax:  (281) 218-9332
    ir@cyberonics.com

SOURCE Cyberonics, Inc.


'/>"/>
SOURCE Cyberonics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cyberonics Provides Update on Depression Post-Approval Study
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Mettler-Toledo International Inc. (NYSE: MTD ) today announced ... highlights: , Sales in local currency increased ... Reported sales decreased 3% as currency reduced sales growth ... per diluted share as reported (EPS) were $4.44, compared ... was $4.65, an increase of 10% over the prior-year ...
(Date:2/4/2016)... Md. , Feb. 4, 2016 In response ... , the FDA,s Deputy Commissioner for Medical Products and Tobacco, ... plan to reassess the agency,s approach to opioid medications. The ... while still providing patients in pain access to effective relief. ... FDA will: , Re-examine the risk-benefit paradigm for ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... 2016 , ... With the FCPX LUT: Summer pack from Pixel ... A LUT is a Lookup Table that contains a mathematical formula for modifying an ... table. By manipulating each pixel, LUT's can change each color range differently, it gives ...
(Date:2/5/2016)... ... ... Love is in the air at King Kullen! The local grocer is offering ... for Valentine’s Day is a must-have, and can be picked up with all other ... long-stem roses available, but also other flower bouquets, elegantly wrapped and ready to go. ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University ... Allen have signed a joint enrollment and degree completion agreement. The agreement, ... and baccalaureate degrees at FHU|Dickson. , The agreement allows students to be ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... franchises from across the country gathered at the La Valencia Hotel in San ... PROSHRED Chicago was named the year’s most outstanding franchise, walking away with ...
Breaking Medicine News(10 mins):